Alnylam Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Conference Transcript
All right. Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here. It's my pleasure to introduce the team from Alnylam Pharmaceuticals. Up to my left, Yvonne Greenstreet, CEO; and to her left is John Kennedy, Senior Vice President of Global Commercialization and lead of the TTR franchise, which I know a lot of people are interested in, so happy to have you both here.
But just a reminder is the fireside chat. If anyone has questions, if you raise your hand, we can try and address them in our discussion. But before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, maybe I'll just hand it over briefly to Yvonne to make some
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
